[{"id":"eaacbaad-f813-44b5-b98c-4ef8fd4a5156","acronym":"","url":"https://clinicaltrials.gov/study/NCT07480863","created_at":"2026-03-28T01:39:30.077Z","updated_at":"2026-03-28T01:39:30.077Z","phase":"Phase 2","brief_title":"Treatment of BTKi+Hi-CVP Regimen for Previously Untreated MZL","source_id_and_acronym":"NCT07480863","lead_sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","biomarkers":" CD20","pipe":" | ","alterations":" CD20 positive","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • vincristine • Inokai (orelabrutinib) • Anruixi (zuberitamab)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 65","initiation":"Initiation: 10/01/2025","start_date":" 10/01/2025","primary_txt":" Primary completion: 10/01/2029","primary_completion_date":" 10/01/2029","study_txt":" Completion: 10/02/2029","study_completion_date":" 10/02/2029","last_update_posted":"2026-03-18"},{"id":"12facf0a-d9fd-4fd1-aec9-b451aa677d4a","acronym":"","url":"https://clinicaltrials.gov/study/NCT06647940","created_at":"2025-02-26T09:23:18.118Z","updated_at":"2025-02-26T09:23:18.118Z","phase":"Phase 2","brief_title":"Orelabrutinib in Combination with R-CHOP for CD5-positive DLBCL Patients（Rocket Trial）","source_id_and_acronym":"NCT06647940","lead_sponsor":"Sun Yat-sen University","biomarkers":" CD5","pipe":"","alterations":" ","tags":["CD5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • Inokai (orelabrutinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 39","initiation":"Initiation: 11/01/2024","start_date":" 11/01/2024","primary_txt":" Primary completion: 11/01/2026","primary_completion_date":" 11/01/2026","study_txt":" Completion: 03/01/2027","study_completion_date":" 03/01/2027","last_update_posted":"2024-10-22"},{"id":"50186f31-5ca5-4488-bd84-bf563991c783","acronym":"","url":"https://clinicaltrials.gov/study/NCT04438005","created_at":"2021-01-18T21:21:51.408Z","updated_at":"2024-07-02T16:35:04.228Z","phase":"Phase 2","brief_title":"A Study of ICP-022 in Patients With R/R DLBCL","source_id_and_acronym":"NCT04438005","lead_sponsor":"Beijing InnoCare Pharma Tech Co., Ltd.","biomarkers":" MYD88 • CD79B","pipe":" | ","alterations":" MYD88 L265P","tags":["MYD88 • CD79B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MYD88 L265P"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Inokai (orelabrutinib)"],"overall_status":"Completed","enrollment":" Enrollment 3","initiation":"Initiation: 05/07/2020","start_date":" 05/07/2020","primary_txt":" Primary completion: 11/05/2021","primary_completion_date":" 11/05/2021","study_txt":" Completion: 12/13/2021","study_completion_date":" 12/13/2021","last_update_posted":"2024-05-13"},{"id":"5d4ae12a-84da-499d-aa62-2349f98e8956","acronym":"","url":"https://clinicaltrials.gov/study/NCT06290817","created_at":"2024-03-04T15:34:19.837Z","updated_at":"2024-07-02T16:35:16.632Z","phase":"Phase 2","brief_title":"Orelabrutinib Combined With R-CDOP for DLBCL Patients With High-risk of CNS Relapse Defined by CNS-IPI","source_id_and_acronym":"NCT06290817","lead_sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","biomarkers":" BCL2","pipe":"","alterations":" ","tags":["BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • Inokai (orelabrutinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 62","initiation":"Initiation: 03/30/2023","start_date":" 03/30/2023","primary_txt":" Primary completion: 03/30/2025","primary_completion_date":" 03/30/2025","study_txt":" Completion: 03/20/2026","study_completion_date":" 03/20/2026","last_update_posted":"2024-03-04"},{"id":"233c1cd3-e615-424d-9090-dec6dee535af","acronym":"BELIEVE-01","url":"https://clinicaltrials.gov/study/NCT05234684","created_at":"2023-10-24T00:13:32.808Z","updated_at":"2024-07-02T16:35:20.333Z","phase":"Phase 3","brief_title":"A Study of Orelabrutinib Plus R-CHOP in Treatment-naïve Patients With MCD Subtype Diffuse Large B-cell Lymphoma","source_id_and_acronym":"NCT05234684 - BELIEVE-01","lead_sponsor":"Beijing InnoCare Pharma Tech Co., Ltd.","biomarkers":" CD20","pipe":" | ","alterations":" CD20 positive","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • Inokai (orelabrutinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 150","initiation":"Initiation: 11/02/2022","start_date":" 11/02/2022","primary_txt":" Primary completion: 07/30/2024","primary_completion_date":" 07/30/2024","study_txt":" Completion: 12/30/2025","study_completion_date":" 12/30/2025","last_update_posted":"2024-02-07"},{"id":"d0c7acc3-5f08-4014-b6ae-dd852fb3d748","acronym":"","url":"https://clinicaltrials.gov/study/NCT04304040","created_at":"2021-01-18T20:52:28.941Z","updated_at":"2024-07-02T16:35:20.402Z","phase":"Phase 1/2","brief_title":"A Study of MIL62 Combined With Orelabrutinib for the Treatment of R/R CD20+B Cell Lymphoma","source_id_and_acronym":"NCT04304040","lead_sponsor":"Beijing InnoCare Pharma Tech Co., Ltd.","biomarkers":" CD20","pipe":" | ","alterations":" CD20 positive","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Inokai (orelabrutinib) • obinutuzumab-β (MIL62)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 43","initiation":"Initiation: 07/28/2020","start_date":" 07/28/2020","primary_txt":" Primary completion: 12/30/2025","primary_completion_date":" 12/30/2025","study_txt":" Completion: 12/30/2025","study_completion_date":" 12/30/2025","last_update_posted":"2024-02-07"},{"id":"49b9bdb6-a946-472f-8310-c49daa2ab094","acronym":"","url":"https://clinicaltrials.gov/study/NCT05495828","created_at":"2022-08-10T12:55:35.171Z","updated_at":"2024-07-02T16:35:31.522Z","phase":"","brief_title":"Orelabrutinib Therapy in Patients With r/r B-cell Lymphoma Intolerant to Other Bruton Tyrosine Kinase Inhibitors","source_id_and_acronym":"NCT05495828","lead_sponsor":"Peking University People's Hospital","biomarkers":" CCND1","pipe":" | ","alterations":" CCND1 expression","tags":["CCND1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CCND1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Inokai (orelabrutinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 11/10/2023","start_date":" 11/10/2023","primary_txt":" Primary completion: 12/10/2024","primary_completion_date":" 12/10/2024","study_txt":" Completion: 03/10/2025","study_completion_date":" 03/10/2025","last_update_posted":"2023-10-26"},{"id":"6aeb4f0c-1118-4c38-821c-7468aa07d2e8","acronym":"","url":"https://clinicaltrials.gov/study/NCT05926427","created_at":"2023-07-03T17:09:25.918Z","updated_at":"2024-07-02T16:35:38.171Z","phase":"Phase 2","brief_title":"Orelabrutinib Combined With Rituximab and Chemotherapy for Relapsed/Refractory B-Cell Lymphoma Patients With Central Nervous System Involvement","source_id_and_acronym":"NCT05926427","lead_sponsor":"Ruijin Hospital","biomarkers":" CD20","pipe":" | ","alterations":" CD20 positive","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • Inokai (orelabrutinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 25","initiation":"Initiation: 08/10/2023","start_date":" 08/10/2023","primary_txt":" Primary completion: 04/30/2026","primary_completion_date":" 04/30/2026","study_txt":" Completion: 04/30/2026","study_completion_date":" 04/30/2026","last_update_posted":"2023-09-04"},{"id":"b6c99686-f03d-4ff2-9afa-ea3e62b00c66","acronym":"","url":"https://clinicaltrials.gov/study/NCT06015464","created_at":"2023-08-29T16:10:09.123Z","updated_at":"2024-07-02T16:35:38.729Z","phase":"","brief_title":"An Ambispective Cohort Study of Orelabrutinib in Combination With Standard Treatment Regimen for Untreated DLBCL","source_id_and_acronym":"NCT06015464","lead_sponsor":"The First Affiliated Hospital with Nanjing Medical University","biomarkers":" NODAL","pipe":"","alterations":" ","tags":["NODAL"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Inokai (orelabrutinib)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 81","initiation":"Initiation: 09/01/2023","start_date":" 09/01/2023","primary_txt":" Primary completion: 12/30/2024","primary_completion_date":" 12/30/2024","study_txt":" Completion: 07/30/2025","study_completion_date":" 07/30/2025","last_update_posted":"2023-08-29"},{"id":"f8215bbc-2e11-42b6-bc92-12e56a7c786f","acronym":"CLL-OBG","url":"https://clinicaltrials.gov/study/NCT05918276","created_at":"2023-06-26T14:09:08.625Z","updated_at":"2024-07-02T16:35:44.689Z","phase":"Phase 2","brief_title":"Clinical Study of Orelabrutinib Combined With BG Regimen First-line Treatment of CLL/SLL","source_id_and_acronym":"NCT05918276 - CLL-OBG","lead_sponsor":"Nanfang Hospital of Southern Medical University","biomarkers":" KIT • CD20","pipe":" | ","alterations":" CD20 positive","tags":["KIT • CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Inokai (orelabrutinib)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 24","initiation":"Initiation: 07/15/2023","start_date":" 07/15/2023","primary_txt":" Primary completion: 12/30/2024","primary_completion_date":" 12/30/2024","study_txt":" Completion: 12/30/2026","study_completion_date":" 12/30/2026","last_update_posted":"2023-06-26"},{"id":"6582ba2f-465f-4ec8-9153-22d9d0cfb77d","acronym":"","url":"https://clinicaltrials.gov/study/NCT03494179","created_at":"2021-01-18T17:12:24.228Z","updated_at":"2024-07-02T16:35:46.491Z","phase":"Phase 1/2","brief_title":"A Study to Evaluate ICP-022 in Patients With R/R Mantle Cell Lymphoma (MCL)","source_id_and_acronym":"NCT03494179","lead_sponsor":"Beijing InnoCare Pharma Tech Co., Ltd.","biomarkers":" CCND1","pipe":" | ","alterations":" Chr t(11;14) • CCND1 overexpression","tags":["CCND1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Chr t(11;14) • CCND1 overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Inokai (orelabrutinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 120","initiation":"Initiation: 04/02/2018","start_date":" 04/02/2018","primary_txt":" Primary completion: 12/31/2023","primary_completion_date":" 12/31/2023","study_txt":" Completion: 12/31/2023","study_completion_date":" 12/31/2023","last_update_posted":"2023-06-05"},{"id":"8b764d74-e563-4c46-9e6c-33001c101645","acronym":"","url":"https://clinicaltrials.gov/study/NCT05051891","created_at":"2021-09-21T11:53:41.573Z","updated_at":"2024-07-02T16:36:02.613Z","phase":"Phase 3","brief_title":"A Randomized, Open-label, Multi-center, Phase III Study of Orelabrutinib in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) vs. R-CHOP Alone in Patients With Treatment-naїve Mantle Cell Lymphoma","source_id_and_acronym":"NCT05051891","lead_sponsor":"Beijing InnoCare Pharma Tech Co., Ltd.","biomarkers":" CD20 • CCND1","pipe":" | ","alterations":" CCND1 expression","tags":["CD20 • CCND1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CCND1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • vincristine • prednisone • Inokai (orelabrutinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 356","initiation":"Initiation: 12/22/2021","start_date":" 12/22/2021","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2027","study_completion_date":" 12/31/2027","last_update_posted":"2022-10-12"},{"id":"b89a0835-124a-4860-a930-5c1a9ff00128","acronym":"O-Gemox","url":"https://clinicaltrials.gov/study/NCT05381506","created_at":"2022-05-19T12:57:05.219Z","updated_at":"2024-07-02T16:36:07.595Z","phase":"Phase 2","brief_title":"Study of Orelabrutinib in Combination With Gemox in Refractory / Relapsed Diffuse Large B-cell Lymphoma","source_id_and_acronym":"NCT05381506 - O-Gemox","lead_sponsor":"Sun Yat-sen University","biomarkers":" CD20","pipe":"","alterations":" ","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e oxaliplatin • Inokai (orelabrutinib)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 77","initiation":"Initiation: 07/01/2022","start_date":" 07/01/2022","primary_txt":" Primary completion: 12/01/2023","primary_completion_date":" 12/01/2023","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2022-07-08"},{"id":"87f5363e-39f5-4e12-a14d-6c37674ba12f","acronym":"CWCLL-001","url":"https://clinicaltrials.gov/study/NCT05322733","created_at":"2022-04-12T14:52:53.816Z","updated_at":"2024-07-02T16:36:11.945Z","phase":"Phase 2","brief_title":"Orelabrutinib and Obinutuzumab Plus FC Regimen in Treating Newly Diagnosed CLL/SLL","source_id_and_acronym":"NCT05322733 - CWCLL-001","lead_sponsor":"The First Affiliated Hospital with Nanjing Medical University","biomarkers":" CD20","pipe":" | ","alterations":" CD20 positive","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Gazyva (obinutuzumab) • cyclophosphamide • Inokai (orelabrutinib) • fludarabine IV"],"overall_status":"Recruiting","enrollment":" Enrollment 25","initiation":"Initiation: 04/15/2022","start_date":" 04/15/2022","primary_txt":" Primary completion: 02/22/2025","primary_completion_date":" 02/22/2025","study_txt":" Completion: 11/05/2025","study_completion_date":" 11/05/2025","last_update_posted":"2022-04-19"},{"id":"5aa1eea1-635b-4d9b-966e-c22735b9bf9d","acronym":"","url":"https://clinicaltrials.gov/study/NCT05097443","created_at":"2021-10-28T17:56:11.820Z","updated_at":"2024-07-02T16:36:20.478Z","phase":"Phase 3","brief_title":"Orelabrutinib, Rituximab and Combination Chemotherapy in Newly-diagnosed Aggressive B-cell Non-Hodgkin Lymphoma","source_id_and_acronym":"NCT05097443","lead_sponsor":"Shandong Provincial Hospital","biomarkers":" BCL2","pipe":"","alterations":" ","tags":["BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • cyclophosphamide • epirubicin • Inokai (orelabrutinib) • vindesine"],"overall_status":"Recruiting","enrollment":" Enrollment 130","initiation":"Initiation: 04/15/2021","start_date":" 04/15/2021","primary_txt":" Primary completion: 12/31/2023","primary_completion_date":" 12/31/2023","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2021-11-19"},{"id":"97a0f864-5b07-4d88-916d-bfe999d83acd","acronym":"","url":"https://clinicaltrials.gov/study/NCT05014100","created_at":"2021-08-20T15:53:11.571Z","updated_at":"2024-07-02T16:36:25.684Z","phase":"Phase 2","brief_title":"Orelabrutinib in Combination With R2 Regimen for R/R CD20+ B-cell Lymphoma","source_id_and_acronym":"NCT05014100","lead_sponsor":"Puyang Oilfield General Hospital","biomarkers":" CD20","pipe":"","alterations":" ","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • lenalidomide • Inokai (orelabrutinib)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 55","initiation":"Initiation: 09/01/2021","start_date":" 09/01/2021","primary_txt":" Primary completion: 09/30/2022","primary_completion_date":" 09/30/2022","study_txt":" Completion: 09/30/2023","study_completion_date":" 09/30/2023","last_update_posted":"2021-08-27"}]